2017年為止的神經變性疾病市場：Aricept、Namenda、Avonex、Rebif、Copaxone等熱銷藥劑因專利失效而造成成長的阻礙

2017年為止的神經變性疾病市場：Aricept、Namenda、Avonex、Rebif、Copaxone等熱銷藥劑因專利失效而造成成長的阻礙 是由出版商GBI Research在2011年10月所出版的。 這份英文市場調查報告書包含Pages: 145 價格從美金3500起跳。

簡介

全球神經變性疾病治療藥市場在2010年達到16億奥2,800萬美元。比起2002年的110億5.500萬美元是以每年CAGR5.4%成長。主要理由是因為壽命擴大造成全球性高齡人口增加。神經變性疾病治療藥產品管道有許多有潛力的新化合物處於各種臨床開發階段，應可滿足未滿足的需求。

本報告書為全球神經變性疾病治療藥市場之相關調査分析、市場全體的動向與歐美、日本等各地區環境、治療領域的市場促進因子與阻礙因子、產品開發管道動向、競爭企業的簡介與M&A動向等整理、概述如下。

第1章 目次

第2章 2017年為止的神經變性疾病市場：導論

第3章 世界市場概要

• 導論
• 收益
  • 副廠藥佔有率
  • 年度治療費
  • 治療使用形態

第4章 各地區環境

• 各地區收益分析
• 美國
• 歐洲主要5國
• 日本

第5章 治療環境

• 阿茲海默症治療藥市場
• 阿茲海默症治療藥市場的促進因子與阻礙因子
• 多發性硬化症治療藥市場
• 多發性硬化症治療藥市場的促進因子與阻礙因子
• 帕金森症治療藥市場
• 帕金森症治療藥市場的促進因子與阻礙因子
• 糖尿病性神經障害治療藥市場
• 糖尿病性神經障害治療藥市場的促進因子與阻礙因子
• 亨廷頓氏症治療藥市場
• 亨廷頓氏症病治療藥市場的促進因子與阻礙因子
• 肌肉萎縮性側索硬化症（ALS）治療藥市場
• 肌肉萎縮性側索硬化症（ALS）治療藥市場的促進因子與阻礙因子

第6章 產品管道評價

• 導論
  • 阿茲海默症
  • 糖尿病性神經障害
  • 多發性硬化症
  • 帕金森症
  • ALS
  • 亨廷頓氏症

第7章 競爭環境

• 市場佔有率分析
• Teva
• Biogen Idec
• Merck Serono
• Bayer Schering Pharma AG
• Novartis
• Boehringer Ingelheim
• Pfizer
  • 企業概要
  • SWOT分析

第8章 M&A環境

• M&A契約（2009∼2010年）
• 認證契約

第9章 附錄

圖表

目錄

Abstract

Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth

Summary

GBI Research, the leading business intelligence provider, has released its latest research "Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth", which provides insights into the Neurodegenerative Disease Market until 2017. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts. The report provides an in-depth analysis of the major neurodegenerative disease including Alzheimer's disease, Multiple sclerosis, Parkinson disease, Diabetic neuropathy and also orphan neurodegenerative diseases such as Huntington's disease and Amyotrophic lateral sclerosis. The report also provides information on the share of generics in Neurodegenerative Disease Markets and examines the global treatment usage patterns for neurodegenerative diseases. In addition, the geographical distribution of neurodegenerative diseases and therapeutics market across the US, the top five countries of Europe and in Japan. The report also includes insights into the neurodegenerative disease therapeutics research and development (R&D) product pipeline and explores the competitive landscape, including major players in the Neurodegenerative Disease Market. Finally, the report also includes analysis of the Mergers and Acquisitions (M&As) and licensing agreements that have taken place in the Neurodegenerative Disease Market.

Scope

• The report analyzes treatment usage patterns, market characterization, pipeline analysis, competitive landscape and key M&A trends in the global neurodegenerative disease market for the six indications that includes Alzheimer's disease, Multiple sclerosis, Parkinson's disease, Diabetic neuropathy and orphan neurodegenerative disease such as Huntington's disease and Amyotrophic lateral sclerosis.
• Data and analysis on the neurodegenerative disease market in the leading geographies of the world - the US, the UK, Germany, France, Italy, Spain, and Japan.
• Annualized market data for the neurodegenerative disease market from 2002 to 2010, with market forecasts to 2017.
• Market data on the geographical landscape and therapeutic landscape, including market size, market share, annual cost of therapy and treatment usage patterns such as disease population, treatment seeking population, diagnosis population and prescription population.
• Share of the generics in global neurodegenerative disease market and for the market of each indication that are covered in the report.
• Key drivers and restraints that have had a significant impact on the market.
• The competitive landscape of the global neurodegenerative disease market including top companies benchmarking. The key companies studied in this report are Teva, Novartis, Merck, Pfizer and Boehringer Ingelheim, Bayer Schering and Biogen Idec.
• Key M&A activities and Licensing Agreements that took place in 2009 and 2010 in the neurodegenerative disease market.

Reasons to buy

The report will assist business development and marketing executives to strategize their product launches, by allowing them to -

• Align your product portfolio to the markets with high growth potential.
• Build effective strategies to launch their pipeline products by identifying potential geographies.
• Exploit in-licensing and out-licensing opportunities by identifying products that might fill their portfolio gaps.
• Develop key strategic initiatives by studying the key strategies of top competitors.
• Device a more tailored country strategy through the understanding of key drivers and barriers and market potential of each indication.
• Develop market-entry and market expansion strategies by identifying the geographic markets poised for strong growth.

Companies Mentioned

• Teva
• Biogen Idec
• Merck Serono
• Bayer Schering Pharma AG
• Novartis
• Boehringer Ingelheim
• Pfizer

1 Table of Contents

1 Table of Contents 4

• 1.1 List of Tables 7
• 1.2 List of Figures 10

2 Neurodegenerative Disease Market to 2017 - Introduction 12

• 2.1 GBI Research Report Guidance 13

3 Neurodegenerative Disease Market to 2017 - Global Market Overview 14

• 3.1 Introduction 14
• 3.2 Revenue 16
• 3.2.1 Generic Share 17
• 3.2.2 Annual Cost of Treatment 18
• 3.2.3 Treatment Usage Patterns 19

4 Neurodegenerative Disease Market to 2017 - Geographical Landscape 21

• 4.1 The US 23
• 4.1.1 Revenue 23
• 4.1.2 Annual Cost of Treatment 24
• 4.1.3 Treatment Usage Patterns 25
• 4.2 Top Five Countries of Europe 27
• 4.2.1 Annual Cost of Treatment 28
• 4.2.2 Treatment Usage Patterns 29
• 4.3 Japan 31
• 4.3.1 Annual Cost of Treatment 32
• 4.3.2 Treatment Usage Patterns 33

5 Neurodegenerative Disease Market to 2017 - Therapeutic Landscape 35

• 5.1 Alzheimer's Disease Therapeutics Market 35
• 5.1.1 Introduction 35
• 5.1.2 Revenue 36
• 5.1.3 Annual Cost of Treatment 40
• 5.1.4 Treatment Usage Patterns 41
• 5.2 Drivers and Restraints to the Alzheimer's Disease Therapeutics Market 43
• 5.2.1 Drivers for Alzheimer's Disease Therapeutics Market 43
• 5.2.2 Restraints for Alzheimer's Disease Therapeutics Market 44
• 5.3 Multiple Sclerosis Market 44
• 5.3.1 Introduction 44
• 5.3.2 Revenue 45
• 5.3.3 Annual Cost of Treatment 49
• 5.3.4 Treatment Usage Patterns 50
• 5.4 Drivers and Restraints to Multiple Sclerosis Market 52
• 5.4.1 Drivers for Multiple Sclerosis Market 52
• 5.4.2 Restraints for Multiple Sclerosis Market 53
• 5.5 Parkinson's Disease Therapeutics Market 53
• 5.5.1 Introduction 53
• 5.5.2 Revenue 53
• 5.5.3 Annual Cost of Treatment 57
• 5.5.4 Treatment Usage Patterns 58
• 5.6 Drivers and Restraints to Parkinson's Disease Therapeutics Market 60
• 5.6.1 Drivers for the Parkinson's Disease Therapeutics Market 60
• 5.6.2 Restraints for the Parkinson's Disease Therapeutics Market 60
• 5.7 Diabetic Neuropathy Market 61
• 5.7.1 Introduction 61
• 5.7.2 Revenue 61
• 5.7.3 Annual Cost of Treatment 65
• 5.7.4 Treatment Usage Pattern 66
• 5.8 Drivers and Restraints to Diabetic Neuropathy Therapeutics Market 68
• 5.8.1 Drivers for Diabetic Neuropathy Market 68
• 5.8.2 Restraints for the Diabetic Neuropathy Therapeutics Market 69
• 5.9 Huntington's Disease Market 69
• 5.9.1 Introduction 69
• 5.9.2 Revenue 70
• 5.9.3 Annual Cost of Treatment 73
• 5.9.4 Treatment Usage Pattern 74
• 5.10 Drivers and Restraints to the Market for Huntington's Disease 76
• 5.10.1 Drivers for Huntington's Disease 76
• 5.10.2 Restraints for Huntington's Disease 77
• 5.11 Amyotrophic Lateral Sclerosis (ALS) Market /Lou Gehrig's Disease 77
• 5.11.1 Introduction 77
• 5.11.2 Revenue 78
• 5.11.3 Annual Cost of Treatment 82
• 5.11.4 Treatment Usage Patterns 83
• 5.12 Drivers and Restraints to Amyotrophic Lateral Sclerosis Market 85
• 5.12.1 Drivers for Amyotrophic Lateral Sclerosis Market 85
• 5.12.2 Restraints for Amyotrophic Lateral Sclerosis Market 86

6 Neurodegenerative Disease Market to 2017 - Product Pipeline Analysis 87

• 6.1 Introduction 87
• 6.1.1 Alzheimer's disease 88
• 6.1.2 Diabetic Neuropathy 101
• 6.1.3 Multiple Sclerosis 103
• 6.1.4 Parkinson's disease 108
• 6.1.5 ALS 115
• 6.1.6 Huntington's disease 117

7 Neurodegenerative Disease Market to 2017 - Competitive Landscape 120

• 7.1 Market Share Analysis 120
• 7.2 Teva 121
• 7.2.1 Company overview 121
• 7.2.2 SWOT Analysis 121
• 7.3 Biogen Idec 122
• 7.3.1 Company Overview 122
• 7.3.2 SWOT Analysis 122
• 7.4 Merck Serono 123
• 7.4.1 Company Overview 123
• 7.4.2 SWOT Analysis 123
• 7.5 Bayer Schering Pharma AG 124
• 7.5.1 Company Overview 124
• 7.5.2 SWOT Analysis 124
• 7.6 Novartis 125
• 7.6.1 Company Overview 125
• 7.6.2 SWOT Analysis 125
• 7.7 Boehringer Ingelheim 126
• 7.7.1 Company Overview 126
• 7.7.2 SWOT Analysis 126
• 7.8 Pfizer 127
• 7.8.1 Company Overview 127
• 7.8.2 SWOT Analysis 127

8 Neurodegenerative Disease Market to 2017 - M&A Landscape 128

• 8.1 M&A Deals (2009-2010) 128
• 8.1.1 M&A Deals by Region 130
• 8.1.2 M&A Deals by Value 131
• 8.1.3 Deal Summary of Top 10 M&A Deals by Value 131
• 8.2 Licensing Deals 134
• 8.2.1 Deal Summary 135

9 Neurodegenerative Disease Market to 2017 - Appendix 138

• 9.1 Market Definitions 138
• 9.2 Abbreviations 138
• 9.3 Research Methodology 139
• 9.3.1 Coverage 139
• 9.3.2 Secondary Research 140
• 9.3.3 Primary Research 140
• 9.3.4 Therapeutic Landscape 141
• 9.3.5 Geographical Landscape 144
• 9.3.6 Pipeline Analysis 144
• 9.3.7 Competitive Landscape 144
• 9.3.8 Expert Panel Validation 144
• 9.4 Contact Us 144
• 9.5 Disclaimer 144
• 9.6 Sources 145

1.1 List of Tables

• Table 1: Neurodegenerative Disease Market, Global, Revenue ($m), 2002-2010 16
• Table 2: Neurodegenerative Disease Market, Global, Revenue Forecasts ($m), 2010-2017 16
• Table 3: Neurodegenerative Disease Market, Global, Annual Cost of Treatment ($), 2002-2010 18
• Table 4: Neurodegenerative Disease Market, Global, Annual Cost of Treatment ($), 2010-2017 18
• Table 5: Neurodegenerative Disease Market, Global, Treatment Usage Patterns (Thousand), 2002-2010 19
• Table 6: Neurodegenerative Disease Market, Global, Treatment Usage Patterns (thousand), 2010-2017 20
• Table 7: Neurodegenerative Disease Market, Global Revenue by Country ($m), 2002-2010 22
• Table 8: Neurodegenerative Disease Market, Global Revenue by Country ($m), 2010-2017 22
• Table 9: Neurodegenerative Disease Market, The US, Revenue ($m), 2002-2010 23
• Table 10: Neurodegenerative Disease Market, The US, Revenue Forecasts ($m), 2010-2017 23
• Table 11: Neurodegenerative Disease Market, The US, Annual Cost of Treatment ($), 2002-2010 24
• Table 12: Neurodegenerative Disease Market, The US, Annual Cost of Treatment ($), 2010-2017 24
• Table 13: Neurodegenerative Disease Market, The US, Treatment Usage Patterns (thousand), 2002-2010 25
• Table 14: Neurodegenerative Disease Market, The US, Treatment Usage Patterns (thousand), 2010-2017 26
• Table 15: Neurodegenerative Disease Market, Top Five Countries of Europe, Revenue ($m), 2002-2010 27
• Table 16: Neurodegenerative Disease Market, Top Five Countries of Europe, Revenue Forecasts ($m), 2010-2017 27
• Table 17: Neurodegenerative Disease Market, Top Five Countries of Europe, Annual Cost of Treatment ($), 2002-2010 28
• Table 18: Neurodegenerative Disease Market, Top Five Countries of Europe, Annual Cost of Treatment ($), 2010-2017 28
• Table 19: Neurodegenerative Disease Market, Top Five Countries of Europe, Treatment Usage Pattern (thousand), 2002-2010 29
• Table 20: Neurodegenerative Disease Market, Top Five Countries of Europe, Treatment Usage Patterns (Thousand), 2010-2017 30
• Table 21: Neurodegenerative Disease Market, Japan, Revenue ($m), 2002-2010 31
• Table 22: Neurodegenerative Disease Market, Japan, Revenue Forecasts ($m), 2010-2017 31
• Table 23: Neurodegenerative Disease Market, Japan, Annual Cost of Treatment ($), 2010-2017 32
• Table 24: Neurodegenerative Disease Market, Japan, Annual Cost of Treatment ($), 2010-2017 32
• Table 25: Neurodegenerative Disease Market, Japan, Treatment Usage Patterns (thousand), 2002-2010 33
• Table 26: Neurodegenerative Disease Market, Japan, Treatment Usage Patterns (thousand), 2010-2017 34
• Table 27: Neurodegenerative Disease Market, Alzheimer's Disease, FDA Approved Cholinesterase Inhibitors, 2010 36
• Table 28: Neurodegenerative Disease Market, Alzheimer's Disease, Global Revenue ($bn), 2002-2010 37
• Table 29: Neurodegenerative Disease Market, Alzheimer's Disease, Global Revenue Forecasts ($bn), 2010-2017 37
• Table 30: Neurodegenerative Disease Market, Alzheimer's Disease, Revenue by Country ($m), 2002-2010 38
• Table 31: Neurodegenerative Disease Market, Alzheimer's Disease, Revenue by Country ($m), 2010-2017 39
• Table 32: Neurodegenerative Disease Market, Alzheimer's Disease, Annual Cost of Treatment ($), 2002-2010 40
• Table 33: Neurodegenerative Disease Market, Alzheimer's Disease, Annual Cost of Treatment ($), 2010-2017 40
• Table 34: Neurodegenerative Disease Market, Alzheimer's Disease, Global Treatment Usage Pattern (Thousand), 2002-2010 41
• Table 35: Neurodegenerative Disease Market, Alzheimer's Disease, Global Treatment Usage Pattern (Thousand), 2010-2017 42
• Table 36: Neurodegenerative Disease Market, Multiple Sclerosis, Global Revenue ($m), 2002-2010 46
• Table 37: Neurodegenerative Disease Market, Multiple Sclerosis, Global Revenue Forecasts ($m), 2010-2017 47
• Table 38: Neurodegenerative Disease Market, Multiple Sclerosis, Revenue by Country ($m), 2002-2010 47
• Table 39: Neurodegenerative Disease Market, Multiple Sclerosis, Revenue by Country ($m), 2010-2017 48
• Table 40: Neurodegenerative Disease Market, Multiple Sclerosis, Annual Cost of Treatment ($), 2002-2010 49
• Table 41: Neurodegenerative Disease Market, Multiple Sclerosis, Annual Cost of Treatment ($), 2010-2017 49
• Table 42: Neurodegenerative Disease Market, Multiple Sclerosis, Global Treatment Usage Pattern (Thousand), 2002-2010 50
• Table 43: Neurodegenerative Disease Market, Multiple Sclerosis, Global Treatment Usage Pattern (Thousand), 2010-2017 51
• Table 44: Neurodegenerative Disease Market, Parkinson's disease, Global Revenue ($m), 2002-2010 54
• Table 45: Neurodegenerative Disease Market, Parkinson's disease, Global Revenue Forecasts ($m), 2010-2017 54
• Table 46: Neurodegenerative Disease Market, Parkinson's Disease, Revenue by Country ($m), 2002-2010 55
• Table 47: Neurodegenerative Disease Market, Parkinson's Disease, Revenue by Country ($m), 2010-2017 56
• Table 48: Neurodegenerative Disease Market, Parkinson's Disease, Annual Cost of Treatment ($), 2002-2010 57
• Table 49: Neurodegenerative Disease Market, Parkinson's Disease, Annual Cost of Treatment ($), 2010-2017 57
• Table 50: Neurodegenerative Disease Market, Parkinson's Disease, Global Treatment Usage Pattern (Thousand), 2002-2010 58
• Table 51: Neurodegenerative Disease Market, Parkinson's Disease, Global Treatment Usage Pattern (Thousand), 2010-2017 59
• Table 52: Neurodegenerative Disease Market, Diabetic Neuropathy, Global Revenue ($m), 2002-2010 62
• Table 53: Neurodegenerative Disease Market, Diabetic Neuropathy, Global Revenue Forecasts ($m), 2010-2017 62
• Table 54: Neurodegenerative Disease Market, Diabetic Neuropathy, Revenue by Country ($m), 2002-2010 63
• Table 55: Neurodegenerative Disease Market, Diabetic Neuropathy, Revenue by Country ($m), 2010-2017 64
• Table 56: Neurodegenerative Disease Market, Diabetic Neuropathy, Annual Cost of Treatment ($), 2002-2010 65
• Table 57: Neurodegenerative Disease Market, Diabetic Neuropathy, Annual Cost of Treatment ($), 2010-2017 65
• Table 58: Neurodegenerative Disease Market, Diabetic Neuropathy, Global Treatment Usage Pattern (Thousand), 2002-2010 66
• Table 59: Neurodegenerative Disease Market, Diabetic Neuropathy, Global Treatment Usage Pattern (Thousand), 2010-2017 67
• Table 60: Neurodegenerative Disease Market, Huntington's Disease, Global Revenue ($m), 2002-2010 70
• Table 61: Neurodegenerative Disease Market, Huntington's Disease, Global Revenue Forecast ($m), 2010-2017 70
• Table 62: Neurodegenerative Disease Market, Huntington's Disease, Revenue by Country ($'000),2002-2010 71
• Table 63: Neurodegenerative Disease Market, Huntington's Disease, Revenue by Country ($'000),2010-2017 72
• Table 64: Neurodegenerative Disease Market, Huntington's Disease, Annual Cost of Treatment ($), 2002-2010 73
• Table 65: Neurodegenerative Disease Market, Huntington's Disease, Annual Cost of Treatment ($), 2010-2017 73
• Table 66: Neurodegenerative Disease Market, Huntington's Disease, Global Treatment Usage Pattern (Thousand), 2002-2010 74
• Table 67: Neurodegenerative Disease Market, Huntington's Disease, Global Treatment Usage Pattern (Thousand), 2010-2017 75
• Table 68: Neurodegenerative Disease Market, Amyotrophic Lateral Sclerosis, Global Revenue ($m), 2002-2010 79
• Table 69: Neurodegenerative Disease Market, Amyotrophic Lateral Sclerosis, Global Revenue Forecasts ($m), 2010-2017 79
• Table 70: Neurodegenerative Disease Market, Amyotrophic Lateral Sclerosis, Revenue by Country ($'000),2002-2010 80
• Table 71: Neurodegenerative Disease Market, Amyotrophic Lateral Sclerosis, Revenue by Country ($'000),2010-2017 81
• Table 72: Neurodegenerative Disease Market, Amyotrophic Lateral Sclerosis, Annual Cost of Treatment ($), 2002-2010 82
• Table 73: Neurodegenerative Disease Market, Amyotrophic Lateral Sclerosis, Annual Cost of Treatment ($), 2010-2017 82
• Table 74: Neurodegenerative Disease Market, Amyotrophic Lateral Sclerosis, Global Treatment Usage Pattern (thousand), 2002-2010 83
• Table 75: Neurodegenerative Disease Market, Amyotrophic Lateral Sclerosis, Global Treatment Usage Pattern (thousand), 2002-2010 84
• Table 76: Neurodegenerative Disease Market, Alzheimer's Disease, Discovery Product Pipeline, 2010 88
• Table 77: Neurodegenerative Disease Market, Diabetic Neuropathy, Product Pipeline, 2010 101
• Table 78: Neurodegenerative Disease Market, Multiple Sclerosis, Product Pipeline, 2010 103
• Table 79: Neurodegenerative Disease Market, Parkinson's Disease, Product Pipeline, 2010 109
• Table 80: Neurodegenerative Disease Market, ALS Product Pipeline,2010 115
• Table 81: Neurodegenerative Disease Market, HD Product Pipeline,2010 118
• Table 82: Neurodegenerative Disease Market, Global, M&A Deals, 2009-2010 128
• Table 83: Neurodegenerative Disease Market, Global, Top Licensing Deals by Value ($m), 2009-2010 134

1.2 List of Figures

• Figure 1: Neurodegenerative Disease Market, Global, Share of Neurodegenerative Disease (%), 2010 14
• Figure 2: Neurodegenerative Disease Market, Global, Revenue Forecasts ($m), 2002-2017 16
• Figure 3: Neurodegenerative Disease Market, Global, Generic Share in Global Neurodegenerative Disease Market,(%), 2010, 2017 17
• Figure 4: Neurodegenerative Disease Market, Global, Annual Cost of Treatment ($), 2002-2017 18
• Figure 5: Neurodegenerative Disease Market, Global, Treatment Usage Patterns (Thousand), 2002-2017 19
• Figure 6: Neurodegenerative Disease Market, Global Revenue by Country ($m), 2002-2017 21
• Figure 7: Neurodegenerative Disease Market, The US, Revenue Forecasts ($m), 2002-2017 23
• Figure 8: Neurodegenerative Disease Market, The US, Annual Cost of Treatment ($), 2002-2017 24
• Figure 9: Neurodegenerative Disease Market, The US, Treatment Usage Patterns (thousand), 2002-2017 25
• Figure 10: Neurodegenerative Disease Market, Top Five Countries of Europe, Revenue Forecasts ($m), 2002-2017 27
• Figure 11: Neurodegenerative Disease Market, Top Five Countries of Europe, Annual Cost of Treatment ($), 2002-2017 28
• Figure 12: Neurodegenerative Disease Market, Top Five Countries of Europe, Treatment Usage Patterns (Thousand), 2002-2017 29
• Figure 13: Neurodegenerative Disease Market, Japan, Revenue Forecasts ($m), 2002-2017 31
• Figure 14: Neurodegenerative Disease Market, Japan, Annual Cost of Treatment ($), 2002-2017 32
• Figure 15: Neurodegenerative Disease Market, Japan, Treatment Usage Patterns (thousand), 2002-2017 33
• Figure 16: Neurodegenerative Disease Market, Alzheimer's Disease, Global Revenue Forecasts ($bn), 2002-2017 37
• Figure 17: Neurodegenerative Disease Market, Alzheimer's Disease, Revenue by Country ($m), 2002-2017 38
• Figure 18: Neurodegenerative Disease Market, Alzheimer's Disease, Generic Share in Alzheimer's Disease Therapeutics Market, 2010, 2017 39
• Figure 19: Neurodegenerative Disease Market, Alzheimer's Disease, Annual Cost of Treatment ($), 2002-2017 40
• Figure 20: Neurodegenerative Disease Market, Alzheimer's Disease, Global Treatment Usage Pattern (Thousand), 2002-2017 41
• Figure 21: Neurodegenerative Disease Market, Alzheimer's Disease, Global Market Drivers and Restraints, 2010-2017 43
• Figure 22: Neurodegenerative Disease Market, Multiple Sclerosis, Global Revenue Forecasts ($m), 2002-2017 46
• Figure 23: Neurodegenerative Disease Market, Multiple Sclerosis, Revenue by Country ($m), 2002-2017 47
• Figure 24: Neurodegenerative Disease Market, Multiple Sclerosis, Generic Share in Multiple Sclerosis Market, (%), 2010, 2017 48
• Figure 25: Neurodegenerative Disease Market, Multiple Sclerosis, Annual Cost of Treatment ($), 2002-2017 49
• Figure 26: Neurodegenerative Disease Market, Multiple Sclerosis, Global Treatment Usage Pattern (Thousand), 2002-2017 50
• Figure 27: Neurodegenerative Disease Market, Multiple Sclerosis, Global Market Drivers and Restraints, 2010-2017 52
• Figure 28: Neurodegenerative Disease Market, Parkinson's Disease, Global Revenue Forecasts ($m), 2002-2017 54
• Figure 29: Neurodegenerative Disease Market, Parkinson's Disease, Revenue by Country ($m), 2002-2017 55
• Figure 30: Neurodegenerative Disease Market, Parkinson's Disease, Generic Share in Parkinson's disease Market, ($m) 2010, 2017 56
• Figure 31: Neurodegenerative Disease Market, Parkinson's Disease, Annual Cost of Treatment ($), 2002-2017 57
• Figure 32: Neurodegenerative Disease Market, Parkinson's Disease, Global Treatment Usage Pattern (Thousand), 2002-2017 58
• Figure 33: Neurodegenerative Disease Market, Parkinson's Disease, Global Market Drivers and Restraints, 2010-2017 60
• Figure 34: Neurodegenerative Disease Market, Diabetic Neuropathy, Global Revenue Forecasts ($m), 2002-2017 62
• Figure 35: Neurodegenerative Disease Market, Diabetic Neuropathy, Revenue by Country ($m), 2002-2017 63
• Figure 36: Neurodegenerative Disease Market, Diabetic Neuropathy, Generic Share in Diabetic Neuropathy Market, ($m) 2010,2017 64
• Figure 37: Neurodegenerative Disease Market, Diabetic Neuropathy, Annual Cost of Treatment ($), 2002-2017 65
• Figure 38: Neurodegenerative Disease Market, Diabetic Neuropathy, Global Treatment Usage Pattern (Thousand), 2002-2017 66
• Figure 39: Neurodegenerative Disease Market, Diabetic Neuropathy, Global Market Drivers and Restraints, 2010-2017 68
• Figure 40: Neurodegenerative Disease Market, Huntington's Disease, Global Revenue Forecast ($m), 2002-2017 70
• Figure 41: Neurodegenerative Disease Market, Huntington's Disease, Revenue by Country ($m),2002-2017 71
• Figure 42: Neurodegenerative Disease Market, Huntington's Disease, Generic Share in Huntington's Disease Market, ($m) 2010,2017 72
• Figure 43: Neurodegenerative Disease Market, Huntington's Disease, Annual Cost of Treatment ($), 2002-2017 73
• Figure 44: Neurodegenerative Disease Market, Huntington's Disease, Global Treatment Usage Pattern (Thousand), 2002-2017 74
• Figure 45: Neurodegenerative Disease Market, Huntington's Disease, Global Market Drivers and Restraints, 2010-2017 76
• Figure 46: Neurodegenerative Disease Market, Amyotrophic Lateral Sclerosis, Global Revenue Forecasts ($m), 2002-2017 79
• Figure 47: Neurodegenerative Disease Market, Amyotrophic Lateral Sclerosis, Revenue by Country ($m),2002-2017 80
• Figure 48: Neurodegenerative Disease Market, Amyotrophic Lateral Sclerosis, Generic Share in ALS Market, (%) 2010,2017 81
• Figure 49: Neurodegenerative Disease Market, Amyotrophic Lateral Sclerosis, Annual Cost of Treatment ($), 2002-2017 82
• Figure 50: Neurodegenerative Disease Market, Amyotrophic Lateral Sclerosis, Global Treatment Usage Pattern (thousand), 2002-2017 83
• Figure 51: Neurodegenerative Disease Market, Amyotrophic Lateral Sclerosis, Global Market Drivers and Restraints, 2010-2017 85
• Figure 52: Neurodegenerative Disease Market, Global Product Pipeline by Indication (%), 2010 87
• Figure 53: Neurodegenerative Disease Market, Global Top Companies Share (%), 2010 120
• Figure 54: Neurodegenerative Disease Market, SWOT Analysis, Teva, 2011 121
• Figure 55: Neurodegenerative Disease Market, SWOT Analysis, Biogen Idec, 2011 122
• Figure 56: Neurodegenerative Disease Market, SWOT Analysis, Merck Serono, 2011 123
• Figure 57: Neurodegenerative Disease Market, SWOT Analysis, Bayer Schering, 2011 124
• Figure 58: Neurodegenerative Disease Market, SWOT Analysis, Novartis, 2011 125
• Figure 59: Neurodegenerative Disease Market, SWOT Analysis, Boehringer Ingelheim, 2011 126
• Figure 60: Neurodegenerative Disease Market, SWOT Analysis, Pfizer, 2011 127
• Figure 61: Neurodegenerative Disease Market, Global, M&A Deals by Region, 2009-2010 130
• Figure 62: Neurodegenerative Disease Market, Global, M&A Deals by Value ($m), 2009-2010 131
• Figure 63: GBI Research Market Forecasting Model 143

相關商品

神經疾病相關市場調查報告書

中樞神經系統(CNS)的罕見疾病治療市場(∼2017年):AMR101和ACR16等新藥提供治療可供選擇，支援亨丁頓舞蹈症市場區隔
Orphan Diseases Therapeutics in CNS to 2017 - Novel Agents such as AMR101 and ACR16 to Provide Treatment Options and Boost the Huntington's Disease Segment
價格 : US $ 3500
出版日期 : 2012年04月

神經保護：醫療藥品・市場・企業
Neuroprotection - Drugs, Markets and Companies
價格 : US $ 5000
出版日期 : 2012年04月

阿茲海默症：新藥・市場・企業
Alzheimer disease - new drugs, markets and companies
價格 : US $ 3500
出版日期 : 2012年04月

GBI Research發行的製藥相關市場調查報告書

學名藥的價格設定與回本:歐洲的緊縮政策與醫療費抑制的創新主導型製藥企業的壓力

Pricing and Reimbursement in Generics - European Austerity Measures and Healthcare Cost Containment Puts Innovation-Driven Pharma Companies under Pressure

價格 : US $ 3500

出版日期 : 2012年04月

到2018年為止的開發業務受託機關 (CRO) 市場:研究能力強化和臨床開發計劃發展的官民合作關係

Contract Research Organizations (CROs) Market to 2018 - Public-Private Partnerships to Strengthen Research Capacities and Advance Clinical Development Programs

價格 : US $ 3500

出版日期 : 2012年04月

到2018年為止的醫藥品受託製造廠商 (CMO) 市場:成本優勢和質量標準提高的信賴建立和對亞洲CMO的外國投資的促進

Contract Manufacturing Organizations to 2018 - Cost Advantages and Improving Quality Standards Build Confidence and Encourage Foreign Investment in Asian CMOs

價格 : US $ 3500

出版日期 : 2012年04月

Email Alert(Email 通知) - 最新市場調查報告書

GII 將每天定期更新最新市場調查報書資訊，選擇您有興趣的市場分類，我們將用Email的方式讓您收到最新訊息!